In this episode, Bernie and Anthony team up with lymphoma experts Dr. Jon Weiss, Dr. James Davis, Dr. Eugene Przespolewski, and Dr. Aaron "Papa Heme" Goodman to discuss the latest updates in the front-line treatment of DLBCL. We critically appraise the frontMIND trial, compare results to the POLARIX study, and discuss the newest press release information about bispecifics in front-line DLBCL treatment!

In this episode, Anthony and Bernie are joined by the great Dr. Bixby to discuss the difficulties in the diagnosis and treatment of acute leukemias of mixed or ambiguous lineage (ALAL/MPAL).

We discuss:

- Diagnostic uncertainties and how the criteria for diagnosis have changed over the years

- Data behind the optimal treatment of MPAL and uncertainties in the literature

- Promising data for the FLAG-VIPR hybrid regimen and other novel treatment strategies

In this episode, Bernie and Anthony are joined by Myeloma Man Manni Mohyuddin, MD to discuss the debate surrounding the treatment of first relapse in multiple myeloma. Should we be using CAR-T? Bispecifics? How does the new mezigdomide data from ASCO 2026 inform our practice? Listen in for a spicy discussion!

Articles discussed:

• Nature Reviews Commentary: https://www.nature.com/articles/s41571-026-01159-6
• CARTITUDE-4: https://www.nature.com/articles/s41571-026-01159-6
• MajesTEC-3: https://www.nejm.org/doi/full/10.1056/NEJMoa2514663

• MajesTEC-9: https://www.nejm.org/doi/abs/10.1056/NEJMoa2603870
• Control arms in multiple myeloma trials: https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2026020329/567836/Improving-Control-Arms-in-2026-U-S-Myeloma-Trials
• Predictors for CAR T cell therapy-associated immune-related adverse events? https://pubmed.ncbi.nlm.nih.gov/41540109/
• Dex prophylaxis for lymphocytosis: https://ashpublications.org/bloodadvances/article/10/10/3629/567462/Dexamethasone-prophylaxis-for-excessive-lymphocyte
• Mezi-KD vs. KD ASCO 2026: https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA7506